Εσθονία - Εσθονικά - Ravimiamet

krka, d.d., novo mesto - fingolimood - kõvakapsel - 0,5mg 60tk; 0,5mg 30tk; 0,5mg 98tk; 0,5mg 28tk; 0,5mg 14tk; 0,5mg 90tk; 0,5mg 100tk

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - sclerosis multiplex, relapsing-remitting - immunosupressandid - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Εσθονία - Εσθονικά - Ravimiamet

sandoz pharmaceuticals d.d. - fingolimood - kõvakapsel - 0,25mg 28tk

Εσθονία - Εσθονικά - Ravimiamet

cangene corporation - tuulerõugete immunoglobuliin - süstelahus - 125rÜ 1.2ml 1.2ml 1tk

Εσθονία - Εσθονικά - Ravimiamet

sanquin, clb, products division - tuulerõugete immunoglobuliin - süstelahus - 100rÜ 1ml 2ml 1tk

Εσθονία - Εσθονικά - Ravimiamet

biotest pharma gmbh - tuulerõugete immunoglobuliin - infusioonilahus - 25rÜ 1ml 5ml 1tk

Εσθονία - Εσθονικά - Ravimiamet

ipsen pharma - botulismitoksiin - süstelahuse pulber - 300ühik 1tk

Εσθονία - Εσθονικά - Ravimiamet

ipsen pharma - botulismitoksiin - süstelahuse pulber - 500ühik 1tk; 500ühik 2tk

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.